Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 46.5 kDa. The protein migrates as 60-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>85% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human TIM-3 (22-200) Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85%.
The purity of Human TIM-3 (22-200) Protein, Fc Tag (Cat. No. TM3-H5258) is more than 90% and the molecular weight of this protein is around 120-150 kDa verified by SEC-MALS.
Immobilized Human TIM-3 (22-200) Protein, Fc Tag (Cat. No. TM3-H5258) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human TIM-3 Antibody, Human IgG4 with a linear range of 0.2-2 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Cobolimab | WBP 296A; TSR-022; GSK-4069889 | Phase 3 Clinical | Anaptysbio Inc | Liver Neoplasms; Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Sabatolimab | MBG-453; NVP-MBG453 | Phase 3 Clinical | Novartis Pharma Ag | Leukemia, Myelogenous, Chronic; Leukemia; Preleukemia; Hematologic Diseases; Leukemia, Myeloid; Polycythemia Vera; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Neoplasms; Primary Myelofibrosis; Bone Marrow Diseases; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
Surzebiclimab | BGB-A425 | Phase 2 Clinical | BeOne Medicines Ltd | Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
Lomvastomig | RG-7769; RO-7121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
BMS-986258 | ONO-7807; BMS-986258 | Phase 2 Clinical | Five Prime Therapeutics Inc, Bristol-Myers Squibb Company | Neoplasms | Details |
Sabestomig | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Hodgkin Disease; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
S-095018 | S095018; S-095018 | Phase 2 Clinical | Servier Bio-Innovation LLC, Institut De Recherches Internationales Servier, Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
LB-1410 | LB-1410 | Phase 2 Clinical | L&L Biopharma Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
TB-006 | TB-006; TB006 | Phase 2 Clinical | TrueBinding Inc | Autism Spectrum Disorder; Coronavirus Disease 2019 (COVID-19); Ischemic Stroke; Alzheimer Disease; Parkinson Disease | Details |
BC-3402 | BC-3402; BC3402 | Phase 2 Clinical | Wuxi BioCity | Hematologic Neoplasms; Solid tumours; Hematologic Diseases; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Carcinoma, Hepatocellular | Details |
TQB-2618 | TQB-2618 | Phase 2 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Lymphoma; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
SHR-1702 | SHR-1702 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
LY-3321367 | LY-3321367 | Phase 1 Clinical | Eli Lilly And Company | Solid tumours | Details |
KL-A293 | KL-A293 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Neoplasms | Details |
NB-002 (Suzhou Luosheng Bio-Pharmaceutical) | NB-002 (Suzhou Luosheng Bio-Pharmaceutical); NB-002 (逻晟生物); NB-002 | Phase 1 Clinical | NeoLogics Bioscience Co Ltd | Solid tumours; Neoplasms | Details |
LPX-TI641 | LPX-TI-641 | Phase 1 Clinical | LAPIX Therapeutics Inc | Autoimmune Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Neuromyelitis Optica; Demyelinating Diseases; Arthritis, Psoriatic | Details |
Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Bis-5 | Phase 1 Clinical | L&L Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
LBL-003 | LBL-003 | Phase 1 Clinical | Nanjing WeiLibo biological Technology Co Ltd | Neoplasms | Details |
Sym-023 | Sym-023; Sym023; S95018 | Phase 1 Clinical | Symphogen A/S | Solid tumours; Lymphoma; Neoplasm Metastasis | Details |
WBP-3425 | WBP-3425 | Phase 1 Clinical | Wuxi BioCity | Solid tumours; Colonic Neoplasms | Details |
This web search service is supported by Google Inc.